Unfortunately nobody cares...this news would have been more significant 1 year ago, even though it is a significant (albeit expected) development which reinforces alliance with GE and business relationship with sole licensee, FIOCRUZ.
Company has an open shelf, ATM financing (at, but realistically below market), needs money, and is facing delisting. I don't think the company will be delisted and I think the company will get the bare minimum injection for short-term interval of survival, however, this will obviously continue to add dead weight to share price.
I love the technology, always have, and think it is incredibly valuable and will be utilized in the future...but not until every existing opportunity within the existing infrastructure is fully exploited, and/or company has something approved or in phase 3, likely to be approved, or enough money to advance candidates through various levels of indications by its own or with legitimate partner.
Management has proved and continues to reinforce incompetence, generally poor decision making, underestimation of business environment, poor execution and under-development of business model, while receiving high salaries and creating negative shareholder value.
Is Bob Erwin still the one-man sales team? An older man with prior unsuccessful business record trying to convince pharma executives that he has the next new thing in biotech (while bob kay manages a hotel)?
Sorry, but the company has now made arrangements with Caliber, the GE alliance is outwardly manifesting, but .57 and nobody cares....
they need too much money over too long a time period with too porous a strategy facing abounding risks, for success as a viable investment vehicle.
I am glad that as a former large shareholder, I got out with minimized losses.